The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice.

Research output: Contribution to journalJournal articlepeer-review

Standard

The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice. / Rolin, Bidda; Deacon, Carolyn F; Carr, Richard D; Ahrén, Bo.

In: European Journal of Pharmacology, Vol. 494, No. 2-3, 2004, p. 283-8.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Rolin, B, Deacon, CF, Carr, RD & Ahrén, B 2004, 'The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice.', European Journal of Pharmacology, vol. 494, no. 2-3, pp. 283-8. https://doi.org/10.1016/j.ejphar.2004.05.013

APA

Rolin, B., Deacon, C. F., Carr, R. D., & Ahrén, B. (2004). The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice. European Journal of Pharmacology, 494(2-3), 283-8. https://doi.org/10.1016/j.ejphar.2004.05.013

Vancouver

Rolin B, Deacon CF, Carr RD, Ahrén B. The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice. European Journal of Pharmacology. 2004;494(2-3):283-8. https://doi.org/10.1016/j.ejphar.2004.05.013

Author

Rolin, Bidda ; Deacon, Carolyn F ; Carr, Richard D ; Ahrén, Bo. / The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice. In: European Journal of Pharmacology. 2004 ; Vol. 494, No. 2-3. pp. 283-8.

Bibtex

@article{08887e10ab4c11ddb5e9000ea68e967b,
title = "The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice.",
abstract = "Glucagon-like peptide-1 (GLP-1), a future treatment for type 2 diabetes, is efficiently degraded by the enzyme dipeptidyl peptidase IV (DPP IV), yielding the major metabolite GLP-1-(9-36)-amide. In this study, we examined the potential glucose lowering effect of GLP-1-(9-36)-amide in mice and found that GLP-1-(9-36)-amide (3 and 10 nmol/kg) did not affect insulin secretion or glucose elimination when administered intravenously together with glucose (1 g/kg). This was observed both in normal mice and in transgenic mice having a complete disruption of the signalling from the GLP-1 receptor. Furthermore, after blocking insulin secretion, using diazoxide (25 mg/kg), no effect on insulin-independent glucose disposal of GLP-1-(9-36)-amide was observed. Therefore, GLP-1-(9-36)-amide does not affect glucose disposal in mice either in the presence or absence of intact GLP-1-receptors or in the presence or absence of stimulated insulin levels. This suggests that the GLP-1 metabolite is not involved in the regulation of glucose homeostasis.",
author = "Bidda Rolin and Deacon, {Carolyn F} and Carr, {Richard D} and Bo Ahr{\'e}n",
note = "Keywords: Animals; Blood Glucose; Diazoxide; Female; Glucagon-Like Peptide 1; Hypoglycemic Agents; Injections, Intravenous; Insulin; Islets of Langerhans; Mice; Mice, Transgenic; Peptides; Potassium Channels; Receptors, Glucagon",
year = "2004",
doi = "10.1016/j.ejphar.2004.05.013",
language = "English",
volume = "494",
pages = "283--8",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2-3",

}

RIS

TY - JOUR

T1 - The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice.

AU - Rolin, Bidda

AU - Deacon, Carolyn F

AU - Carr, Richard D

AU - Ahrén, Bo

N1 - Keywords: Animals; Blood Glucose; Diazoxide; Female; Glucagon-Like Peptide 1; Hypoglycemic Agents; Injections, Intravenous; Insulin; Islets of Langerhans; Mice; Mice, Transgenic; Peptides; Potassium Channels; Receptors, Glucagon

PY - 2004

Y1 - 2004

N2 - Glucagon-like peptide-1 (GLP-1), a future treatment for type 2 diabetes, is efficiently degraded by the enzyme dipeptidyl peptidase IV (DPP IV), yielding the major metabolite GLP-1-(9-36)-amide. In this study, we examined the potential glucose lowering effect of GLP-1-(9-36)-amide in mice and found that GLP-1-(9-36)-amide (3 and 10 nmol/kg) did not affect insulin secretion or glucose elimination when administered intravenously together with glucose (1 g/kg). This was observed both in normal mice and in transgenic mice having a complete disruption of the signalling from the GLP-1 receptor. Furthermore, after blocking insulin secretion, using diazoxide (25 mg/kg), no effect on insulin-independent glucose disposal of GLP-1-(9-36)-amide was observed. Therefore, GLP-1-(9-36)-amide does not affect glucose disposal in mice either in the presence or absence of intact GLP-1-receptors or in the presence or absence of stimulated insulin levels. This suggests that the GLP-1 metabolite is not involved in the regulation of glucose homeostasis.

AB - Glucagon-like peptide-1 (GLP-1), a future treatment for type 2 diabetes, is efficiently degraded by the enzyme dipeptidyl peptidase IV (DPP IV), yielding the major metabolite GLP-1-(9-36)-amide. In this study, we examined the potential glucose lowering effect of GLP-1-(9-36)-amide in mice and found that GLP-1-(9-36)-amide (3 and 10 nmol/kg) did not affect insulin secretion or glucose elimination when administered intravenously together with glucose (1 g/kg). This was observed both in normal mice and in transgenic mice having a complete disruption of the signalling from the GLP-1 receptor. Furthermore, after blocking insulin secretion, using diazoxide (25 mg/kg), no effect on insulin-independent glucose disposal of GLP-1-(9-36)-amide was observed. Therefore, GLP-1-(9-36)-amide does not affect glucose disposal in mice either in the presence or absence of intact GLP-1-receptors or in the presence or absence of stimulated insulin levels. This suggests that the GLP-1 metabolite is not involved in the regulation of glucose homeostasis.

U2 - 10.1016/j.ejphar.2004.05.013

DO - 10.1016/j.ejphar.2004.05.013

M3 - Journal article

C2 - 15212985

VL - 494

SP - 283

EP - 288

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -

ID: 8417367